Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.

@article{Huang2014PreventionOR,
  title={Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.},
  author={Kelly J. Huang and Herren Wu},
  journal={Microbiology spectrum},
  year={2014},
  volume={2 4},
  pages={
          AID-0014-2014
        }
}
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract disease in infants and young children. Initial efforts to develop a vaccine to prevent RSV lower respiratory tract disease in children were halted because of serious adverse events that occurred when children were infected with RSV following vaccination, including vaccine-related deaths. Subsequently, a major focus for researchers was to understand what led to these adverse events. Investment in a vaccine for RSV… 
View on PubMed
asmscience.org
3 Citations
Background Citations
2

3 Citations

Citation Type

Citation Type

Strategies to develop vaccines of pediatric interest
TLDR
The most important vaccines of pediatric interest that are currently being developed are discussed and it is likely that some of them will reach the market in the future and will thus partially contribute to the prevention of very severe diseases that significantly affect the morbidity and mortality of children.
Anticorpos contra a proteína de ligação em Duffy (PvDBP) e proteção contra a malária vivax na Amazônia rural brasileira.
TLDR
This thesis tested whether naturally acquired antibodies to PvDBPII conferred protection against clinical vivax malaria in rural Amazonians exposed to low-level malaria transmission and found that subjects with high blocking activity had a delay in their time to the next v Vivax malaria episode, compared with subjects with low- level inhibitory activity.
Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein
TLDR
These findings suggest that IgG+ memory B cell activity in individuals with P. vivax strain–transcending Abs to DBPII display a limited clonal response with inhibitory blocking directed against a distinct region of the molecule.

References

SHOWING 1-10 OF 112 REFERENCES
Burden of respiratory syncytial virus infection in young children.
  • B. Resch
  • Medicine, Biology
    World journal of clinical pediatrics
  • 2012
TLDR
Palivizumab, a monoclonal RSV antibody that is the only tool for immunoprophylaxis in high-risk infants, lowers the burden of RSV infection in certain carefully selected patient groups.
Maternal antibody and respiratory syncytial virus infection in infancy
TLDR
Babies born to mothers with high levels of IgG antibody to respiratory syncytial virus were protected against infection with this virus during the first months of life when the risk of severe disease was greatest.
Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion
TLDR
Results indicate that these antibodies may prevent conformational changes in F protein required for the fusion process in RSV, and suggest that they block both cell- to-cell and virus-to-cell fusion.
Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
TLDR
RSV can induce substantial neutralizing antibody responses in young infants when the titer of preexisting antibodies is low, and Multivariate analysis demonstrated that the level of preeXisting neutralizing antibodies at infection, not age, was the most important factor influencing this response.
Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus.
TLDR
Although maternalneutralizing antibody did not prevent infection with RSV and illness, the severity of pneumonia caused by RSV was inversely related to the level of neutralizing antibody.
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease
Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection.
TLDR
It is suggested that nose-drop application of monoclonal antibody could provide convenient and effective protection against RSV infection in human infants at risk of severe lower respiratory tract disease.
Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children.
TLDR
A statistical analysis of titers revealed that antibody to the fusion protein is an important correlate of immunity, and the children with less RSV disease had significantly higher IgG anti-F titers prior to infection.
Respiratory Syncytial Virus (RSV) Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections
TLDR
RSVIG treatment was safe but not efficacious in the treatment of children with bronchopulmonary dysplasia, congenital heart disease, or premature gestation who were hospitalized with RSV LRI.
Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
TLDR
RSVIG treatment was safe but not efficacious in the treatment of children with bronchopulmonary dysplasia, congenital heart disease, or premature gestation who were hospitalized with RSV LRI.
...
1
2
3
4
5
...